Transgenomic has renewed a collaboration with Fiuotecnica of Italy, to produce and market a genetic panel assay to predict the risk of cardiovascular disease and heart attacks using the Wave System
As part of the collaboration, Transgenomic will supply its Wave System technology and related reagents to Fiuotecnica.
Upon completion of the assay development, Fiuotecnica will retain rights to market the cardiovascular panel in Italy, while Transgenomic will obtain rights to market the assay in the rest of the world.
Antonio Mele, CEO of Fiuotecnica, stated: "We are pleased to be able to reaffirm our collaboration with Transgenomic.
"Fiuotecnica has evaluated other platforms, but we believe that Transgenomic's unique technology platforms, including the Wave System for DHPLC analysis and Surveyor Nuclease, provide the highest sensitivity for mutation detection.
"Our decision to work with Transgenomic as a partner has been affirmed by the Italian Ministry of University and Research, which is supporting this important work.
"We feel the cardio assay is only the beginning, and we look forward to expanding our collaboration to include other panels in the future".
Transgenomic's CEO, Craig Tuttle, stated: "We are pleased to enter into this strategic collaboration with Fiuotecnica.
"Fiuotecnica's choice of Transgenomic as a partner to develop this cardio panel provides further validation of our core technologies in the European market, where we have always enjoyed an advantage.
"Furthermore, we believe the cardio assay for predictive analysis of myocardial infarctions will be an important addition to our Transgenomic Laboratories's Clia genetic screening offerings to hospitals and clinicians."
